Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

(2013) Mark A. Dickson et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design

(2011) Darren R. Feldman et al.   CANCER

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers

(2010) Elodie E. Noel et al.   AMERICAN JOURNAL OF PATHOLOGY

Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal

(2010) Andrea Necchi et al.   BJU INTERNATIONAL

Treatment of Growing Teratoma Syndrome

(2009) David J. Vaughn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Medical Treatment of Advanced Testicular Cancer

(2008) Darren R. Feldman   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION